Cagrilintide/semaglutide - Novo Nordisk
Alternative Names: CagriSema; NN-9388; Semaglutide/Cagrilintide - Novo NordiskLatest Information Update: 07 Aug 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Amylin receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
- Phase II Alcoholic liver disorders
Most Recent Events
- 07 Aug 2024 Novo Nordisk plans a phase III REIMAGINE 5 trial for Type 2 diabetes mellitus (Adjunctive treatment) in USA, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain and Taiwan (SC) in November 2024 (NCT06534411)
- 17 Jul 2024 Phase-III clinical trials in Type 2 diabetes mellitus in Poland, Serbia, China (SC) prior to July 2024 (NCT06323174)
- 17 Jul 2024 Phase-III clinical trials in Obesity in Argentina, Brazil, Colombia, France, Germany, India, Malaysia, Mexico, Netherlands, Poland, Serbia, South Africa, and Turkey (SC) prior to July 2024 (NCT05669755)